A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a COVID-19 mRNA Vaccine in Adults Aged 50 Years and Above

Clinical trial NCT06374394 · COMPLETED

Trial details

NCT number: NCT06374394
Sponsor: GlaxoSmithKline
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Respiratory Syncytial Virus Infections

Start date: 2024-04-29
Primary completion: 2024-11-01
Enrollment: 841

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.